Atovaquone and Proguanil — Competitive Intelligence Brief

Atovaquone and Proguanil (Atovaquone and Proguanil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial [EPC].

marketed Antimalarial [EPC] Small molecule

Target snapshot

Atovaquone and Proguanil (Atovaquone and Proguanil) — State University of New York - Upstate Medical University.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atovaquone and Proguanil TARGET	Atovaquone and Proguanil	State University of New York - Upstate Medical University	marketed	Antimalarial [EPC]
Coartem	LUMEFANTRINE	Novartis	marketed	Antimalarial [EPC]	Potassium voltage-gated channel subfamily H member 2	2009-01-01
Coartem	ARTEMETHER		marketed	Antimalarial [EPC]		2009-01-01
Qualaquin	QUININE	Sun Pharm Industries	marketed	Antimalarial	Sodium channel alpha subunits; brain (Types I, II, III)	2005-01-01
Malarone	PROGUANIL	GSK	marketed	Antimalarial [EPC]		2000-01-01
Halfan	HALOFANTRINE	GSK	marketed	Antimalarial	Potassium voltage-gated channel subfamily H member 2	1992-01-01
Mepron	ATOVAQUONE		marketed	Antimalarial [EPC]	ATP-binding cassette sub-family G member 2	1992-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial [EPC] class)

1. · 2 drugs in this class
2. GSK · 1 drug in this class
3. Novartis · 1 drug in this class
4. State University of New York - Upstate Medical University · 1 drug in this class